BTC 
ETH 
XRP
SOL 
DOGE - This topic is empty.
-
Posts
-
AstraZeneca agreed on Monday, Sept 28 to invest $2 billion in Summit Therapeutics (SMMT), buying newly issued convertible preferred shares at an $18.36-per-common-share equivalent — about 18.6% above Monday’s $15.48 close. Summit shares jumped as much as 19% in after-hours trading, ending the cash scare that had hung over the biotech since July.
What happened
AstraZeneca is buying the preferred shares at a 10% premium to the five-day VWAP, with the transaction expected to close by end of the week; on conversion, AZN would hold rights to roughly 12% of Summit’s outstanding common stock (about 10.6% fully diluted). The deal adds a clinical collaboration testing Summit’s ivonescimab with AstraZeneca’s antibody-drug conjugate sonesitatug vedotin in gastrointestinal cancers — AZN sponsors the trials and costs are split — plus a non-binding MOU that opens the door to pairing ivonescimab with other AZN cancer medicines.
Critically, this is a strategic stake and collaboration, not a buyout: AstraZeneca gets no rights to Summit’s lead drug. Ivonescimab is a PD-1/VEGF bispecific antibody licensed ex-China from Akeso in December 2022 in a deal worth up to $5 billion; it is already approved in China, and an FDA decision is expected by Nov 14 on ivonescimab plus chemotherapy for certain non-small cell lung cancer patients. Summit had flagged in July that its cash pile was not enough to fund a full year of planned operations — the $2 billion ends that overhang.
- Investment: $2B at $18.36/share equivalent — 18.6% above Monday’s $15.48 close
- After-hours reaction: SMMT up as much as 19%; AZN’s U.S. shares up ~1%
- Stake on conversion: ~12% of Summit common stock (10.6% fully diluted)
- FDA catalyst: decision on ivonescimab in lung cancer expected by Nov 14
Why it matters
This is a $2 billion validation of the PD-1/VEGF bispecific thesis from a Big Pharma leader — one of the largest strategic bets on the mechanism to date. It de-risks Summit’s funding runway while preserving upside optionality, since AZN takes no ownership of the lead asset. Expect copycat dealmaking: late-stage biotech names with differentiated oncology platforms just became partnership or acquisition targets.
What to watch
Closing of the $2 billion investment this week, the FDA decision by Nov 14 on ivonescimab in lung cancer, and the start of the first GI-cancer combination trials with sonesitatug vedotin.
Related reading: Zenbexus: Bristol Myers Drug Doubles Deep Responses in Myeloma Phase 3
Sources: Reuters, Dow Jones / Morningstar
Auto-posted by the Bull Lounge news desk.
Not financial advice.Is SMMT a hold into the Nov 14 FDA decision after a 19% after-hours pop, or is the validation already priced in?
Log in to vote
